↓ Skip to main content

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2013
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)

Mentioned by

twitter
2 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
Published in
Journal for Immunotherapy of Cancer, November 2013
DOI 10.1186/2051-1426-1-s1-p127
Authors

Howard Burris, Stephen Ansell, John Neumanitis, Geoffrey Weiss, Branimir Sikic, Donald Northfelt, Lana Pilja, Thomas Davis, Michael Yellin, Tibor Keler, Timothy Bullock

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 18%
Professor > Associate Professor 1 9%
Other 1 9%
Unknown 7 64%
Readers by discipline Count As %
Agricultural and Biological Sciences 2 18%
Immunology and Microbiology 1 9%
Medicine and Dentistry 1 9%
Unknown 7 64%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2013.
All research outputs
#10,045,823
of 17,897,867 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,259
of 1,833 outputs
Outputs of similar age
#93,860
of 198,176 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#34
of 43 outputs
Altmetric has tracked 17,897,867 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,833 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.7. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,176 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.